Thu, Oct 2, 2014, 7:14 AM EDT - U.S. Markets open in 2 hrs 16 mins

Recent

% | $
Quotes you view appear here for quick access.

Sanofi Message Board

biotech_invest 194 posts  |  Last Activity: Sep 30, 2014 1:04 PM Member since: Mar 5, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • biotech_invest biotech_invest Sep 30, 2014 1:04 PM Flag

    one more thing: current MNKD 3 months chart (decline) will "scare" any trade software from automatic buying. These programs are designed to sniff only growing stocks and will never buy "falling knife" stocks. Only funds that not use trade software will buy MNKD at this situation. And may be there were designers for this declining chart? They have most valuable thing - they know exact time when MNKD pps may spike (Q1, 2015). Bloodsuckers that hunt retail investors.

    Sentiment: Strong Buy

  • Like saint_rick33
    14 posts | Last Activity: 16 hours ago
    Member since: Sep 29, 2014

    that wrote recently:

    "When or if ever Afrezza gains traction, oral insulin will be shortly around the corner
    And afrezza will by obsolete"

    It's a big mistake to answer to such "new-born" members because they are mostly paid bashers.
    I already put all MB members since 2014 on ignore and thinking about some members since 2013.

    After this it will be easy to target old bashers farters like opc11 that Member since: Feb 4, 1999
    opc11
    1556 posts | Last Activity: 55 minutes ago

    they usually have 1000 posts for last 3 months

    Also ignore them.

    That is it. You have basher-free MNKD MB.

    Sentiment: Strong Buy

  • What kind of false fears bashers and shorts will invent now for forcing longs to sell MNKD for $6?
    Well, may be "dead money"? I.e. each day longs open MNKD chart and see the same pps (like in "Groundhog Day") during weeks and months. And they hope that after 1-2 months longs will sell MNKD for $6. To funds that accumulate MNKD and shorts that will cover and have a gain $2-3 per share.
    Naive idiots - nobody will sell MNKD even if stubborn shorts will decrease pps to $5 or below. MNKD already got $150M upfront and will get $700M after milestones (sure EMA is one of them). Only one million Afrezza prescriptions in USA = 2 billion annual sales (35% to MNKD).
    I don't know any other biotech that is so safe for long-term (6 months - 1 year) investment. $6 now and $25 in September 2015 is very modest prediction.

    Sentiment: Strong Buy

  • biotech_invest biotech_invest Sep 29, 2014 8:30 PM Flag

    There is only known biotech company that claimed that they can make oral insulin: ORMP (public). This company is 100% scam created by mother and son Kidrons to fool investors and become rich. It's useless to explain to you that prandial and rapid acting oral insulin is impossible. However, basal oral insulin may will work but bioavailability will be too low and effective tablets will be very expensive.
    So, if you believe in oral insulin pills buy ORMP for $7.50 now and keep it 2-3 years. If you are right you will be rich. GL

  • volume answers: very negligible number of MNKD retail investors are worrying about current MNKD pps and there will not be any MNKD panic sell off. MNKD longs are waiting for Q3 2015, EMA filing and Q1 2015 AFREZZA launch. Nobody will sell "golden eggs" to funds/institutions that created an "illusion of falling knife" for MNKD.

    Sentiment: Strong Buy

  • biotech_invest biotech_invest Sep 21, 2014 1:40 PM Flag

    it's interesting. May you send me link to contact@biotechinvest.net?
    MNKD pps is artificially low now and I think that most probable reason is a scenario of "falling knife" and "dead money" that funds/institutions are playing to collect cheap shares from retail investors. Naked shorting is a good tool to keep MNKD pps under control.

    Sentiment: Strong Buy

  • Reply to

    Cost of insulin vs. Afrezza

    by antimatter0007 Sep 12, 2014 1:18 PM
    biotech_invest biotech_invest Sep 12, 2014 2:08 PM Flag

    all your calculations are correct and fund's analysts know it.
    AFREZZA is a unique and will be highly demanded by diabetes patients. But it needs time and good advertisement (Sanofi will do the best one).
    Diabetes patients will like AFREZZA because now they can hiking and have snack any time, have an occasional dinners with friends and don;t worry about insulin injection before meal, put AFREZZA in pocket, use it during 10 days and forget about refrigerator...
    With needleless glucose monitors AFREZZA may completely avoid hyper after-meal events.
    Really 21 century drug. Dr. Mann will be remembered because of AFREZZA invention and pushing it through many obstacles and barriers to final FDA approval.
    Question is why MNKD pps is still declining? Or better question: Cui bono? Who is interesting in lowering MNKD pps? Answer is simple: BIG MONEY (including Mann) that already have almost 70% of MNKD shares.
    Nobody will sell stock with growing pps. But almost everybody will sell stock with pps that permanently decline ("who will catch falling knife" or other terms invented by BM).

    Sentiment: Strong Buy

  • Reply to

    third time to post this

    by bandaidman44 Sep 12, 2014 7:25 AM
    biotech_invest biotech_invest Sep 12, 2014 11:40 AM Flag

    Thanks!
    I hope I will never use AFREZZA (nobody can be sure 100%) but will advice future AFREZZA users to buy Microlife Peak Flow Meter Complete Kit for Spirometry with FEV1 + Analyzer Software CD with USB Cable + 2 Free... (current cost $58). It's very simple and convenient device that will remember all your FEV1 data (Automatically stores 240 readings i.e. before AFREZZA use and during the usage). Also needleless glucose monitoring with GlucoWatch G2 Biographer (FDA approved) or GlucoTrack (approved in Europe) will help to monitor AFREZZA in action i.e. each 10 minutes glucose concentration in blood post-meal. AFREZZA works so fast that can stop post-meal glucose spike in real time - one puff and after 15 minutes diabetes patients will see glucose decline. It will never happens with "fast-acting" injectable insulin (Tmax = 60-90 minutes).

    Sentiment: Strong Buy

  • biotech_invest biotech_invest Sep 12, 2014 11:18 AM Flag

    LOL! What are you doing for a life? I hope not thinking and produce new ideas...
    Any way thanks for "not explaining" :-) I'm so tired from a stupidity of paid bashers.
    Just go to your janitor job and don't WASTE your time.

    Sentiment: Strong Buy

  • Reply to

    third time to post this

    by bandaidman44 Sep 12, 2014 7:25 AM
    biotech_invest biotech_invest Sep 12, 2014 11:11 AM Flag

    very clever statement!
    Just one question for you (if you are a primary care physician): what is an approximate cost of FEV1 measurement at doctor office? I'm doing it sometimes with simple handheld device (device cost around $50 and time of measurement 1 second) and know that PCP will do it easy for each diabetes patient. However, some stupid bashers said that it will be main obstacle for PCP to prescribe AFREZZA.
    Thanks in advance for response.

    Sentiment: Strong Buy

  • biotech_invest biotech_invest Sep 12, 2014 10:59 AM Flag

    didn't catch you point... Are you racist? What is "Obama math"?

    Sentiment: Strong Buy

  • biotech_invest biotech_invest Sep 12, 2014 10:55 AM Flag

    do you have problems with arithmetic, moron? It's so simple to calculate that even Psycho Analyst at SA did it correctly:
    "However, since Sept. 2, the average daily volume of MNKD shares traded has only been 4.854 million. So the actual days to cover for the stock, trading at the rate it has been trading recently, is a robust 15.25--more than three weeks of trading. You can examine the volume numbers here: wwwDOTnasdaqDOTcom/symbol/mnkd/historical"
    About dumbness: you are just 1 year MB member and usually it's good proof that you are paid basher here. I'm investing in biotech last 5 years and mostly successfully. You can't prove that you are smart but I can do it very easy and even without expose my real identity.
    So, your opinion is nothing for me and other MB members that really own MNKD shares.

    Sentiment: Strong Buy

  • with volume 3-4M per day they will need at least 20-25 days to cover. Any positive news will catalyze massive accumulation of MNKD by funds/institutions (they already have 80M shares and want more).
    Basher that hired by shorts are playing with several lies like "MNKD is dead money now", "doctors are to lazy to do FEV1 measurements (2 times per year and cost almost nothing) for each patient who want AFREZZA" and etc. Too weak lies and time will tell that all these bashers are just ugly liars.
    Best strategy for MNKD holders now is just relax and add more MNKD at low.

    Sentiment: Strong Buy

  • Reply to

    short interest decline by

    by theman3311 Sep 10, 2014 4:20 PM
    biotech_invest biotech_invest Sep 10, 2014 4:51 PM Flag

    shorts are lucky - they have 5-6 months for covering. If 7-8M per month they will cover 40-50M at Q1 2015.
    But funds and institutions will continue MNKD accumulation during these 5-6 months (now they have almost 90M shares and may double their positions to 180M). We will see soon how short covering will compete with accumulation by institutions and retail investors. MNKD shares are crazy cheap now but good news (like EMA filing, AFREZZA production, AFREZZA advertisement on TV) are coming.
    If 2-3 million diabetes patients start to use meal AFREZZA in Q1-2 2015 MNKD pps will spike to $17 and higher. And Sanofi will not wait for higher pps

    Increased Positions 126 14,676,771
    Decreased Positions 60 8,074,713
    Held Positions 22 66,421,587
    Total Institutional Shares 208 89,173,071

    Sentiment: Strong Buy

  • Even Zacks Equity Research mislead investors
    Everybody knows that so-called "positive results" were just meeting of the primary endpoint of SAFETY and TOLERABILITY.
    But PBT2 practically failed to meet secondary but most important points - efficacy. Highest dose PBT2 was able to improve the cognition of Huntington's patients versus placebo in only one of eight separate tests -- the Trail Making Test Part B. ONE OF EIGHT is just statistical noise.
    Indeed, FDA has granted orphan drug designation to its Huntington disease candidate PBT2. But when FDA refused to grant such status? PRAN just asked about status and FDA gave it. FDA gave this status based on some special criteria (below) but not on drug candidate efficacy.
    However, run up for next HD trial is possible and it will be easy money. Just don't forget to sell PRAN before HD trial results release and then short it at high. Results: double gain.

    "The Orphan Drug Designation program provides orphan status to drugs and biologics which are defined as those intended for the safe and effective treatment, diagnosis or prevention of rare diseases/disorders that affect fewer than 200,000 people in the U.S., or that affect more than 200,000 persons but are not expected to recover the costs of developing and marketing a treatment drug."

    Sentiment: Strong Sell

  • biotech_invest biotech_invest Sep 8, 2014 10:12 PM Flag

    PLUG? LOL! I'm investing only in biotech. PLUG never was in my list. You are liar.
    EDAP failed because of FDA corruption: now USA prostate cancer patients have only one option: radical prostatectomy and as side-effect impotence in 70% cases. EDAP was risky investment and I usually put small money in such investment.
    But MNKD is OK: most promising biotech stock now (I will add more). In Q1-2 2015 PRAN pps will be around $2 but MNKD pps will be doubled.
    Any way continue your pumping - it's so big fun to read your posts about future success of PBT2 in both AD and HD trials :-) I will use future PRAN run ups (AD/HD) to make some easy money. It was so easy last time: did money on both run up and pps crash after AD trial results. Of course it was less than "600,000" that our genius rkf302 did on PRAN.

    Sentiment: Strong Sell

  • biotech_invest biotech_invest Sep 8, 2014 6:40 PM Flag

    I see 6 green ratings on your post and it looks like that entire team of PRAN pumpers already clicked:
    1) rkf302, 2) interestingtome, 3) esoteric687, 4) tb00tb00a, 5) alzwatch, 6) pivalde (iruleyoulose #7 but can't mark his own post)
    Your team is working hard to pump PRAN-scam
    interestingtome: "Pfizer (PFE) Is Talking To Prana Biotechnology (PRAN)" LOL! Idiot, Pfizer even doesn't know what is Prana
    iruleyoulose: "Prana HD = $1B - $2B in annual revenue alone" Sweet dreams of senile farter that put all his retirement money in PRAN at $12 pps
    iruleyoulose: "Acquisition offer this week?? By Pfizer?" Indeed, it's time to visit psychiatrist but may it's too late...
    rkf302: "There are no trials. Oh except the Alzheimer's trial. Oh well yhey don't have any others...except the new Huntington trial... " Well, I see signs of AD here: "Different kinds of real words and pronounceable pseudowords (PWs) were presented for writing to dictation to patients with the diagnosis of probable Alzheimer's disease (AD) and to age- and education-matched healthy controls"
    rfk302, ask your doctor to check your brain for AD and then order PBT2 and eat it 300 mg 3 times per day
    Poor PRAN pumpers, you will never see your money again :-) Even if post 100 times per day that PBT2 is cure for AD and HD nobody will believe in this nonsense.

    Sentiment: Strong Sell

  • biotech_invest biotech_invest Sep 8, 2014 3:50 PM Flag

    LOL! Firstly, I never use other IDs. And (2) I'm not interesting in PRAN-scam nowt. It's too bored biotech stock. HD update was useless and pps will decline again to $2 level. I'll wait for next HD trial (as usually play with run up and then short before trial results). PBT2 will not cure any diseases because it's fake drug. However, scam biotechs might very profitable for smart biotech investors.
    You PRAN pumpers please continue to pump. Your hope that PRAN pps will see again $12 and higher. Naive old farters :-)

    Sentiment: Strong Sell

  • Every 70 seconds, someone in the U.S. develops Alzheimer's disease. There is no cure, but there is new hope.
    Nasal spray for Alzheimer's is in clinical trial and it's just fast-acting insulin. But we know that AFREZZA is fastest insulin on the market now. Sanofi/MNKD should initiate phase I/II for AD patients with AFREZZA. Any positive signs i.e. decreasing of AD-induced cognition decline will make AFREZZA "super-blockbuster".
    It's not pumping - check Yahoo and you will see.
    So, keep MNKD shares tight - pps may grow even faster than Regeneron pps (20X for 5 years).

    Sentiment: Strong Buy

  • Reply to

    Everyone please give it a rest....

    by astavrinos Sep 5, 2014 4:32 PM
    biotech_invest biotech_invest Sep 5, 2014 10:51 PM Flag

    right, even if all longs on MB will repeat again and again mantra "MNKD AFREZZA is revolutionary diabetic drug" pps will not respond and grow fast.
    I'm 100% sure that practically all diabetes patients (without COPD and asthma) will want to try AFREZZA. And doctors always prescribe drugs that patients want. FEV1 measurement is cheap and easy at any doctor office.
    Also many patients know about possibility to monitor blood glucose without needles: 1) GlucoWatch G2 Biographer; 2) GlucoTrack. They can compare head-to-head rapid acting AFREZZA with so-called "fast-acting" injectable insulins. Just eat same meal and one time puff AFREZZA and another time inject meal insulin. And observe glucose profile. Seeing is believing.
    So pumping of MNKD is useless. Time will tell everything. 6-8 months. Nothing in comparison with 10 years development of really ultra-rapid acting inhalable insulin.

    Sentiment: Strong Buy

SNY
55.88-0.55(-0.97%)Oct 1 4:06 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.